The Effect of Autologous Autovaccine in Patients With Allergy on House-dust-mite
Phase 1
Completed
- Conditions
- Allergens, House Dust Mites
- Interventions
- Biological: Injection of autovaccine (Autovaccine Symbiopharm)
- Registration Number
- NCT00677209
- Lead Sponsor
- Johann Wolfgang Goethe University Hospital
- Brief Summary
House dust mite allergy is a common problem, resulting in asthma, chronic swelling of the eyes, and running nose. The investigators test a possibility to immunize subjects sensitized against house dust mite with extracts from their own gut bacteria "auto-vaccination".
- Detailed Description
see above
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 8
Inclusion Criteria
- informed consent
- age 18-35 years
- known allergy on house-dust mite
- GINA 0-1
Exclusion Criteria
- anamnestic incompatibility to parts of autovaccine
- asthma > GINA I°
- chronic disease conditions or infections
- pregnancy
- inhalative or systemic steroid use
- any immunosuppressive therapy
- intake of any other probiotic medication (e.g. E.coli nissle 1917)
- participation in any other study at the same time
- substance abuse
- Incapability of understanding the study's purpose and performance
- smoker
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description A Injection of autovaccine (Autovaccine Symbiopharm) house dust mite allergics will undergo autovaccine immunization
- Primary Outcome Measures
Name Time Method Patients' clinical parameters and behaviour, laboratory values jul 2006 - august 2008 laboratory testing reflecting function of bone marrow, liver, kidney jul 2006- august 2008
- Secondary Outcome Measures
Name Time Method Lung function,exhalative NO jul 2006 - oct 2007
Trial Locations
- Locations (1)
Goethe University, Department of Pulmonology
🇩🇪Frankfurt, Hessen, Germany